
What is claimed is:

1. A compound of the formula (II)



$x\ H_2O$ (II)

2. The compound of claim 1 which shows in the X-ray diffractometry a peak maximum of the 2 Theta angel of 21.2.

3. The compound of claim 1 which shows in the FIR spectrum a peak maximum of 353 cm^{-1}.

4. A process for the preparation of the compound of the formula (II) of any of claims 1 to 3 which comprises dissolution of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide and adding water until precipitation.

5. The preparation of the compound of the formula (II) of any of claims 1 to 3 which comprises suspension of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide in an aqueous solvent and then stirring or shaking until conversion to the compound of the formula (II).

6. A compound of the formula (II) of any of claims 1 to 3 for the treatment of hyper-proliferative disorders.

7. A compound of the formula (II) of any of claims 1 to 3 for the treatment of solid tumors, lymphomas, sarcomas, leukemias, cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid and/or parathyroid.

8. A use of the compound of the formula (II) of any of claims 1 to 3 for the preparation of a pharmaceutical composition for the treatment of hyper-proliferative disorders.

9. The use of claim 8 for the treatment of solid tumors, lymphomas, sarcomas, leukemias, cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid and/or parathyroid.

10. A pharmaceutical composition comprising the compound of the formula (D) of any of claims 1 to 3 mainly, no significant fractions of another form of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2- carboxamide and one or more inert, nontoxic, pharmaceutically suitable excipients.

11. The pharmaceutical composition of claim 10 containing more than 90 percent by weight of the compound of the formula (D) of any of claims 1 to 3 related to the total amount of the compound of the formula (II) present in the composition.

12. The pharmaceutical composition of any of claims 10 or 11 for the treatment of disorders.

13. A combination comprising the compound of the formula (II) of any of claims 1 to 3 and one or more other pharmaceutical agents.


14. The combination of claim 13 wherein the one or more other pharmaceutical agents are cytotoxic agents, signal transduction inhibitors, anti-cancer agents, or antiemetics.

15. The pharmaceutical composition of any of claims 10 to 12 comprising one or more other pharmaceutical agents.

16. The pharmaceutical composition of claim 15 wherein the one or more other pharmaceutical agents are anti-hyper-proliferative agents, cytotoxic agents, signal transduction inhibitors, anti-cancer agents and/or antiemetics.

Claims

1. A compound of the formula (II)



$x\ H_2O$ (II)

2. The compound of claim 1 which shows in the X-ray diffractometry a peak maximum of the 2 Theta angel of 21.2.

3. The compound of claim 1 which shows in the FIR spectrum a peak maximum of 353 cm^{-1}.

4. A process for the preparation of the compound of the formula (II) of any of claims 1 to 3 which comprises dissolution of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide and adding water until precipitation.

5. The preparation of the compound of the formula **(II)** of any of claims 1 to 3 which comprises suspension of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide in an aqueous solvent and then stirring or shaking until conversion to the compound of the formula (II).

6. A compound of the formula (II) of any of claims 1 to 3 for the treatment of hyper-proliferative disorders.

7. A compound of the formula (II) of any of claims 1 to 3 for the treatment of solid tumors, lymphomas, sarcomas, leukemias, cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid and/or parathyroid.

8. A use of the compound of the formula **(II)** of any of claims 1 to 3 for the preparation of a pharmaceutical composition for the treatment of hyper-proliferative disorders.

9. The use of claim 8 for the treatment of solid tumors, lymphomas, sarcomas, leukemias, cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid and/or parathyroid.

10. A pharmaceutical composition comprising the compound of the formula (II) of any of claims 1 to 3 mainly, no significant fractions of another form of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide and one or more inert, nontoxic, pharmaceutically suitable excipients.

11. The pharmaceutical composition of claim 10 containing more than 90 percent by weight of the compound of the formula (II) of any of claims 1 to 3 related to the total amount of the compound of the formula (II) present in the composition.

12. The pharmaceutical composition of any of claims 10 or 11 for the treatment of disorders.

13. A combination comprising the compound of the formula (II) of any of claims 1 to 3 and one or more other pharmaceutical agents.

14. The combination of claim 14 wherein the one or more other pharmaceutical agents are cytotoxic agents, signal transduction inhibitors, anti-cancer agents, or antiemetics.

15. The pharmaceutical composition of any of claims 10 to 12 comprising one or more other pharmaceutical agents.

16. The pharmaceutical composition of claim 16 wherein the one or more other pharmaceutical agents are anti-hyperproliferative agents, cytotoxic agents, signal transduction inhibitors, anti-cancer agents and/or antiemetics.